Collaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510, Raleigh, NC, USA.
Collaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510, Raleigh, NC, USA.
Drug Discov Today. 2023 Oct;28(10):103723. doi: 10.1016/j.drudis.2023.103723. Epub 2023 Jul 22.
Over 3 years, the SARS-CoV-2 pandemic killed nearly 7 million people and infected more than 767 million globally. During this time, our very small company was able to contribute to antiviral drug discovery efforts through global collaborations with other researchers, which enabled the identification and repurposing of multiple molecules with activity against SARS-CoV-2 including pyronaridine tetraphosphate, tilorone, quinacrine, vandetanib, lumefantrine, cetylpyridinium chloride, raloxifene, carvedilol, olmutinib, dacomitinib, crizotinib, and bosutinib. We highlight some of the key findings from this experience of using different computational and experimental strategies, and detail some of the challenges and strategies for how we might better prepare for the next pandemic so that potential antiviral treatments are available for future outbreaks.
在过去的 3 年里，SARS-CoV-2 大流行导致近 700 万人死亡，全球感染人数超过 7.67 亿。在此期间，我们这家规模很小的公司通过与其他研究人员的全球合作，为抗病毒药物发现工作做出了贡献，从而鉴定和重新利用了多种对 SARS-CoV-2 具有活性的分子，包括吡喹酮四磷酸盐、替洛隆、盐酸奎宁、凡德他尼、盐酸左旋咪唑、十六烷基吡啶氯、雷洛昔芬、卡维地洛、奥卢米特尼、达克替尼、克唑替尼和博舒替尼。我们强调了使用不同计算和实验策略的一些关键发现，并详细介绍了我们如何更好地为下一次大流行做准备，以便为未来的疫情提供潜在的抗病毒治疗方法的一些挑战和策略。
